New Scientific Evidence Presented at ANESTHESIOLOGY 2026 Strengthens the Case for Senzime's TetraGraph and Quantitative Neuromuscular Monitoring
Source: Accesswire
Article summary
UPPSALA, SE AND SAN DIEGO, CA / ACCESS Newswire / October 17, 2026 / Senzime (STO:SEZI) (OTCQX:SNZZF) Senzime AB (publ), a global leader in precision-based patient monitoring solutions, today announced new scientific data presented at ANESTHESIOLOGY® 2026, the annual meeting of the American Society of Anesthesiologists (ASA). The research highlights important clinical and economic aspects of quantitative neuromuscular monitoring, including the benefits of Senzime's proprietary TetraGraph® technology.
accessnewswire.com · Opens in a new tab
Summary supplied by the publisher. Read the full story at the source.